




The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 172% points. The greatest weakness of GYRE Therapeutics INC is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 378%, being 135% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	93,606
Cost of Goods Sold	0
Intangible Assets	97
Liabilities, Current	10,979
Liabilities, Non-Current	283
Other Assets	51,488
Other Compr. Net Income	-114
Other Expenses	7.0
Other Liabilities	0
Other Net Income	518
Other Revenues	3,629
Property and Equipment	682
Research and Development	38,840
Selling, General and Administrative Expense	12,005

Output Variable	Value in 1000 USD
Assets	145,873
Liabilities	11,262
Expenses	50,852
Revenues	3,629
Stockholders Equity	134,611
Net Income	-46,705
Comprehensive Net Income	-46,762
BaseVar	106,124
ECR before Limited Liability	314%
Economic Capital Ratio	378%